DocumentCode :
77044
Title :
Sculpting drugs [Medicine Computer Modelling]
Author :
Saint, Amanda
Volume :
9
Issue :
8
fYear :
2014
fDate :
Sept. 2014
Firstpage :
80
Lastpage :
83
Abstract :
We now live in a ´Big Data´ world and computational modelling of biological data, or computational biology, is seeing new approaches, developments and revelations in the way we discover, deliver and understand the effect of drugs. Although Pfizer has withdrawn its takeover bid for AstraZeneca, the progress that it has made in its cancer immunotherapy research using computational biology was one of the key reasons that Pfizer was interested. It´s also a very big part of why AstraZeneca was able to resist the takeover bid. Computational biology has come on in leaps and bounds in the past few years as supercomputing and biomedical data have combined to great effect to improve our understanding of a range of things from how the body will react to drugs to why natural substances such as green tea are good for us, and also to reveal the links between certain games and diseases.
Keywords :
drugs; pharmaceutical industry; pharmaceutical technology; product development; AstraZeneca; Pfizer; biomedical data; cancer immunotherapy research; computational biology; sculpting drugs; supercomputing;
fLanguage :
English
Journal_Title :
Engineering & Technology
Publisher :
iet
ISSN :
1750-9637
Type :
jour
DOI :
10.1049/et.2014.0812
Filename :
6905649
Link To Document :
بازگشت